Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)

被引：0

作者：

Wang, M.

Bensinger, W.

Martin, T.

Alsina, M.

Siegel, D. S. D.

Gabrail, N. Y.

Hari, P.

Singhal, S.

Vescio, R. A.

Assouline, S. E.

Kunkel, L. A.

Vallone, M.

Wong, A.

Niesvizky, R.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[5] John Theurer Canc Ctr, Hackensack, NJ USA

[6] Gabrail Canc Ctr, Canton, OH USA

[7] Med Coll Wisconsin, Miwaukee, WI USA

[8] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA

[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[10] McGill Univ, Jewish Gen Hosp, Clin Res Unit, Segal Canc Ctr,Lady Davis Inst, Montreal, PQ H3T 1E2, Canada

[11] ACT Biotech Inc, San Francisco, CA USA

[12] Onyx Pharmaceut, San Francisco, CA USA

[13] Onyx Pharmaceut, Emeryville, CA USA

[14] Cornell Univ, New York Presbyterian Hosp, Ctr Excellence Lymphoma & Myeloma, Weill Med Coll, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.8025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8025

引用

页数：1

共 50 条

[21] Results From The CC-220-MM-001 Dose-Expansion Phase Of Iberdomide Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
Lonial, Sagar
Popat, Rakesh
Hulin, Cyrille
Jagannath, Sundar
Oriol, Albert
Richardson, Paul G.
Facon, Thierry
Weisel, Katja
Larsen, Jeremy T.
Minnema, Monique
Abdallah, Al-Ola
Badros, Ashraf Z.
Knop, Stefan
Stadtmauer, Edward A.
Chen, Min
Nguyen, Tuong Vi
Amin, Alpesh
Peluso, Teresa
van de Donk, Niels W. C. J.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 38 - 39
[22] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Moreau, P.
Richardson, P.
Jakubowiak, A.
Jagannath, S.
Raab, M.
Facon, T.
Vij, R.
Reece, D.
White, D.
Benboubker, L.
Zonder, J.
Rossi, J. F.
Tsao, C.
Parli, T.
Kroog, G.
Singhal, A.
Lonial, S.
HAEMATOLOGICA, 2012, 97 : 474 - 474
[23] Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)
Jagannath, Sundar
Vij, Ravi
Stewart, A. Keith
Somlo, George
Jakubowiak, Andrzej
Reiman, Tony
Trudel, Suzanne
Taylor, Jessica
Fuhrman, Diana
Cruickshank, Scott
Schwartz, Richard
Kunkel, Lori
Siegel, David
BLOOD, 2008, 112 (11) : 319 - 319
[24] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc S.
Facon, Thierry
Vij, Ravi
Moreau, Philippe
Reece, Donna E.
White, Darrell J.
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn
Singhal, Anil K.
Richardson, Paul G.
BLOOD, 2011, 118 (21) : 141 - 142
[25] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Sara Bringhen
Roberto Mina
Anna Maria Cafro
Anna Marina Liberati
Stefano Spada
Angelo Belotti
Gianluca Gaidano
Francesca Patriarca
Rossella Troia
Renato Fanin
Lorenzo De Paoli
Giuseppe Rossi
Alessandra Lombardo
Paola Bertazzoni
Antonio Palumbo
Pieter Sonneveld
Mario Boccadoro
Leukemia, 2018, 32 : 1803 - 1807
[26] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Bringhen, Sara
Mina, Roberto
Cafro, Anna Maria
Liberati, Anna Marina
Spada, Stefano
Belotti, Angelo
Gaidano, Gianluca
Patriarca, Francesca
Troia, Rossella
Fanin, Renato
De Paoli, Lorenzo
Rossi, Giuseppe
Lombardo, Alessandra
Bertazzoni, Paola
Palumbo, Antonio
Sonneveld, Pieter
Boccadoro, Mario
LEUKEMIA, 2018, 32 (08) : 1803 - 1807
[27] RESULTS OF PX-171-004, AN ONGOING OPEN-LABEL, PHASE II STUDY OF CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (R/R MM) WITH OR WITHOUT PRIOR BORTEZOMIB EXPOSURE
Stewart, K.
Siegel, D.
Wang, M.
Kaufman, J.
Jakubowiak, A.
Jagannath, S.
Kukreti, V.
McDonagh, K.
Alsina, M.
Bahlis, N.
Belch, A.
Gabrail, N.
Le, M.
Bennett, M.
Vij, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 452 - 452
[28] A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort
Berdeja, Jesus G.
Gregory, Tara K.
Faber, Edward A.
Hart, Lowell L.
Mace, Joseph R.
Arrowsmith, Edward R.
Flinn, Ian W.
Matous, Jeffrey V.
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : 428 - 435
[29] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
Schey, Steve
Dhanasiri, Sujith
Lee, Dawn
Sternas, Lars
Yu, Xin
Zaki, Mohamed H.
Elvidge, Jamie
O'Dwyer, Michael
BLOOD, 2014, 124 (21)
[30] Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study
Offidani, Massimo
Corvatta, Laura
Marconi, Monica
Visani, Giuseppe
Alesinai, Francesco
Brunori, Marino
Galieni, Piero
Catarini, Massimo
Burattini, Maurizio
Centurioni, Riccardo
Rupoli, Serena
Scortechini, Anna Rita
Giuliodori, Luciano
Candela, Marco
Capelli, Debora
Montanari, Mauro
Olivieri, Attilio
Piersantelli, Maria-Novella
Leoni, Pietro
HAEMATOLOGICA, 2006, 91 (01) : 133 - 136

← 1 2 3 4 5 →